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Abstract
Background: Herpes simplex virus type-2 (HSV-2) is one of the most common sexually transmitted infections that
facilitate human immunodeficiency virus (HIV) acquisition by over two fold or more. The development of HSV-2
control methods as a measure to control HIV epidemic in high HSV-2/HIV areas has become a priority. Two out of
the six high HIV prevalent states of India are located in the Northeastern region of India. Due to lack of
documented HSV-2 studies from this part of the country; there was a need for estimating the seroprevalence and
risk factors of HSV-2 infection in this defined population.
Methods: Pregnant women (n = 1640) aged18 years and above attending antenatal clinics of tertiary referral
hospitals in five Northeastern states of India were screened for type specific HSV-2 IgG antibodies. Blood samples
were collected from all the participants after conducting interviews. Univariate and multivariate analyses were
performed to identify the risk factors associated with HSV-2 seropositivity.
Results: Overall seroprevalence of HSV-2 infection was 8.7% (142/1640; 95% CI 7.3-10.0) with a highest
prevalence of 15.0% (46/307; 95% CI 11.0-19.0) in the state of Arunachal Pradesh. Higher seroprevalence was
observed with increasing age (Adj. Odds Ratio [AOR] 1.9 for 22-25 years old, AOR 2.29 for > 29 years old). The
risk factors associated with HSV-2 seropositives were multiple sex partners (AOR 2.5, p = 0.04), condom non-
user’s (AOR 4.7, p <0.001), early coitarchal age (age of first intercourse) ‘less than 18 years’ (AOR 9.6, p=0.04),
middle income group (AOR 2.1, p=0.001) compared to low income group and low level of education (AOR 3.7,
p=0.02) compared to higher education. HSV-2 seropositivity was higher among Christians (12.6%) compared to
Muslims (3.8%). The most frequent clinical symptoms among HSV-2 seropositives were excess vaginal discharge
in last one year (53.5%, 76/142) and pelvic pain (26.1%, 37/142). While among subjects with genital ulcers, HSV-2
seroprevalence was 36.8% (7/19).
Conclusions: Overall seroprevalence of HSV-2 infection among pregnant women of Northeast India is relatively
low. The generation of awareness among high risk groups may have played key role to limit the infection. The role
of vaccination against HSV-2 in near future and elimination of HSV-2 viral shedding along with genital tract
inflammation in high HIV/HSV-2 areas may be an option for initiating successful intervention strategies to reduce
the transmission and acquisition of HIV infection in Northeast India.
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Herpes Simplex Virus Type-2 (HSV-2) infections is almost
always sexually transmitted and is the common cause of
genital ulcer disease (GUD) worldwide [1,2]. It is also a
good marker of sexual behavior in the population [1,2].
Seroprevalence studies show wide variations in infection
rates by geographic location. Highest prevalence of HSV-2
has been found in some parts of Africa, America and the
lowest in Asia [3]. Globally about 535.5 million were
infected with HSV-2 with an overall prevalence of 16.2%
in 2003 [4]. The HSV-2 prevalence in South-Asia in 2003
was estimated to be 29.4% and 33.2% among males and
females in the age group of 15-49 years respectively [4].
Recent study from India shows HSV-2 prevalence among
general population to be around 10% [5]. HSV-2 is gaining
special attention as a significant risk factor for acquisition
of human immunodeficiency virus type-1 (HIV-1). HSV-2
infection is also present in 30 to 70% of those in Europe
and 50 to 90% of those in Africa among patients with HIV
infection [6]. HSV-2 increases the risk of HIV-1 transmis-
sion by more than two fold and HIV transmission on a
per-sexual act basis by up to fivefold and may account for
40 - 60% of new HIV infections in high HSV-2 prevalent
populations [7-14]. It is assumed that infection with HSV-
2 disrupts the genital mucosa and provides a portal of
entry for HIV, leading to increased susceptibility of HIV in
HIV-negative persons. Also, HSV-2 is thought to enhance
HIV acquisition due to dense inflammatory infiltrates of
CD4/CD8/dendritic cells in the genital tract associated
with HSV-2 shedding [15]. Moreover, in HIV-positive per-
sons, infection with HSV-2 accelerates replication and
genital shedding of the virus, thus such individuals are
more likely to transmit HIV [16,17]. Increasing evidence
of HSV-2 facilitating HIV acquisition and transmission
makes the development of HSV control methods a priority
[1,6]. Also, other meta-analysis data from general popula-
tion among women showed that in prevalent HSV-2 infec-
tion, HIV acquisition increased by over a three-fold [18]. A
study by Nagot et al. highlights the association of HSV-2
with significantly higher viral load of HIV-1 in plasma and
in genital secretions in women with sexually acquired
HIV-1 [17]. This finding has direct clinical implications,
suggesting that elimination of HSV-2 viral shedding and
genital tract inflammation can reduce the transmission
and acquisition of HIV infection.
The role of HSV-2 as a biological cofactor in HIV acqui-
sition and transmission, which may have contributed sub-
stantially to HIV infections particularly by facilitating HIV
spread among the low-risk population with stable long-
term sexual partnerships [19]. A study conducted in four
cities of Africa indicated that in the two West African
cities with lower HSV-2 prevalence, HIV remained con-
centrated in higher risk groups. However, in the cities
with high HSV-2 prevalence, HIV transmission was
observed in a large fraction of the population [20]. These
results suggest that HSV-2 may be the trigger for the
explosive expansion of HIV and were also corroborated by
the epidemiological synergy study of HIV and HSV-2 [19].
The increasing evidence that HSV-2 facilitates HIV acqui-
sition and transmission and the synergistic effect of
HSV-2 on HIV, makes the development of HSV-2 control
methods a priority.
In Northeast India, the epidemic of HIV-1 is driven
mainly by the IDU population in the State of Manipur,
Mizoram and Nagaland. The state of Manipur has the
highest HIV prevalence in the country (1.67% in 2006)
[21]. In a recent study from this Institute, the HIV-1 pre-
valence was found to vary between 23%-32% among the
IDUs of Manipur [22]. Female sex workers (FSWs) are
common in scattered locations in few northeast states of
India. One recent study from this Institute has found
HIV-1 prevalence of 13.6% in FSWs of Nagaland, a state
in northeast India (unpublished data of the authors). The
population of Northeast India is heterogeneous and there
is a huge socio-cultural difference among the states. HIV
preventive measures have been the cornerstone in the
efforts to halt the epidemic amongst IDUs and FSWs of
Northeast India. Over the years, HIV has made in-roads
into the general population of the Northeastern states.
The average HIV prevalence among women attending
antenatal clinics in India is 0.48%. The HIV prevalence in
the antenatal clinic attendees in the Northeastern state of
Manipur was 1.25% and in Mizoram was 1.0% in 2006,
which was among the highest in the country in this
group of population [21].
Considering the above facts, this study was conducted
to assess the seroprevalence of HSV-2 and its risk factors
among pregnant women (antenatal clinic attendees) in
five North-eastern states of India (viz. Assam, Arunachal
Pradesh, Manipur, Meghalaya, and Mizoram). Since,
more than 75% of primary genital herpes virus infections
are asymptomatic [23], the seroepidemiological studies
are critical in understanding the pattern and distribution
of infection within the population to understand the
HSV-2 related HIV transmission dynamic in the different
communities of Northeast India.
Methods
Study area and Population
This is a cross-sectional study which was conducted in
five, out of eight Northeastern states of India to under-
stand the epidemiology and role of risk factors associated
with HSV-2 seroprevalence with an aim focused towards
prevention. A total of 1640 pregnant woman attending
antenatal clinics (ANCs) in five tertiary referral hospitals
representing the general population of each of the five
Northeastern states i.e., Arunachal Pradesh, Assam,
Manipur, Meghalaya, and Mizoram were enrolled in the
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study was approved by institutional human ethical com-
mittee of the Regional Medical Research Centre. Trained
field investigators had enrolled pregnant women aged 18
years and above who had consented for the study. Preg-
nant women in labor or under serious medical conditions
were excluded from the study.
Data collection
A predesigned and pretested structured questionnaire
having information on socio-demographic variables such
as age, religion, education, occupation, type of family,
geographic location, annual income, gestational weeks,
and risk factors that may be associated with sexually
transmitted diseases like number of sex partners in pre-
vious one year, use of condom, alcohol consumption, coi-
tarchal age, commercial sex worker, and type of sex
partner were recorded. The clinical history, signs &
symptoms associated with genito-pelvic infections,
including previous history of genital ulcer, pelvic pain,
and excessive vaginal discharge, pain during sexual inter-
course, genital warts, and swelling in the groin were also
recorded. The participants were interviewed confiden-
tially and examined by qualified gynaecologists.
Specimen collection and laboratory test
Specimen of 5 ml venous blood were collected from all
the enrolled subjects in K3 EDTA tubes and immediately
kept at +4°C. Plasma samples were separated on the
same day and stored at -20°C freezer in aliquots until
analyzed. Plasma samples were subjected for HSV-2 IgG
detection using type specific HSV-2 glycoprotein (gpG2)
IgG EIA kit (HerpeSelect 2 ELISA IgG, Focus Diagnos-
tics, USA) as per manufacture’s manual. The cut-off
value used to determine a positive test on this kit was >
1.10. Index value between 1.1 and 0.9 were considered
equivocal and index values below 0.9 were considered
negative as per the kit instruction manual. The equivocal
samples were re-tested with the same kit. The samples
that were found to be equivocal in the repeat test, a sec-
ond samples were collected from the same subjects after
1-2 months for reconfirmation. All the positive samples
and randomly selected 10% negative samples were re-
tested for confirmation.
Statistical analyses
Data were entered and analyzed in SPSS version 13.0
statistical software (SPSS, Chicago, USA). The statistical
significance of HSV-2 seroprevalence with other asso-
ciated factors (socio-demographic, risk variables and
clinical findings) was obtained using univariate analysis.
The multivariate analysis was performed by binary logis-
tic regression using Wald Backward elimination method
with probability for stepwise entry at p =0 . 0 5a n d
removal at p = 0.1, to find the association between cate-
gorical variables with HSV-2 seroprevalence. Odds ratios
(OR) were calculated using Binary logistic regression
analysis where first category (having lowest seropreva-
lence) was used as a reference in each group. OR and
their 95% confidence intervals (95% CI) were documen-
ted to indicate magnitude and direction of associations.
The variables showing significant interactions were ana-
lyzed separately. The level of statistical significance was
set at p ≤ 0.05.
Results
A total of 1640 pregnant women from five Northeastern
states of India were studied. The median age of the
study subjects was 25 years (SD ± 4.7) and ranged from
18 to 46 years. The literacy rate of the enrolled subjects
was 84.5% (n = 1386), among which 49.3% (n = 809)
were educated up to primary level. Majority of the sub-
jects were housewife 79.9% (n = 1310), lived in nuclear
family 57.9% (n = 950), and were from low income
group 71.8% (n = 1177). Within the enrolled subjects,
67.0% (n = 1099) were in 3
rd trimester of pregnancy and
43.2% (n = 708) were primi-gravida with a median of
two gravida (2 ± 1.8).
State-wise, socio-demographic variables of the study
subjects are listed in Table 1. The demographic composi-
tion in the present study reveals that Christians
accounted for the major chunk of subjects in the state of
Mizoram (96.1%), Meghalaya (70.0%) followed by Aruna-
chal Pradesh (35.2%), whereas Hindus followed by Mus-
lims were found to be the major religion of the study
cohort in Assam (90.3% and 8.7%) and Manipur (86.1%
and 13.9%) respectively. Also, it was observed that 84.9%
of the enrolled Muslim subjects were from low income
group compared to 49.4% and 39.5% in Hindus and
Christians respectively. Overall 11.7% (192/1640)
enrolled subjects were migrants with highest number in
Arunachal Pradesh (19.9%) followed by Meghalaya
(19.5%) and Mizoram (10.8%).
Seroprevalence
The overall HSV-2 seroprevalence was 8.7% (142/1640;
95% CI 7.3-10.0) with a highest prevalence of 15.0%
(95% CI 11.0-19.0) in the state Arunachal Pradesh fol-
lowed by Mizoram at 13.4% (95% CI 9.0-17.8), Megha-
laya at 10.5% (95% CI 7.5-13.5), Assam at 4.0% (95% CI
1.8-6.2) and Manipur at 2.7% (95% CI 1.1-4.3). The
increasing HSV-2 seroprevalence was observed with the
increasing age e.g. 6.5% seroprevalence in ‘18-21 years’
age group to 9.4% in ‘29 years and above’ with a signifi-
cant peak of 10.5% in ‘22-25 years’ (Table 2). HSV-2 ser-
oprevalence was 17.9% (approaching significance p =
0.06) in 1st trimester of pregnancy compared to 6.8% in
2nd and 9.3% in 3rd trimester. Though HSV-2
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compared to the locals (8.2%), it was not significant sta-
tistically (p = 0.08).
Risk Factors
The univariate and multivariate analysis of risk factors
associated with HSV-2 seroprevalence is presented in
Table 2. In univariate analysis, it was found that HSV-2
seroprevalence differs significantly (p < 0.001) among
the subjects of different religion in North-east India.
Subjects from Christian community were at higher risk
(AOR 3.5, 95% CI 1.2-10.1, p = 0.02) of getting infection
with reference to Muslims (analyzed separately because
of significant interaction with ‘state’). On multivariate
analysis, it was found that subjects in the state of Aru-
nachal Pradesh has the highest risk of HSV-2 compared
to the state of Manipur (AOR 11.5, 95% CI 5.2-25.5, p <
0.001). The risk-factors that had a significant association
with HSV-2 were condom never users compared to reg-
ular or occasional users (AOR, 4.7, 95% CI 2.5-8.9, p <
0.001); coitarchal age less than 18 years (AOR 9.6, 95%
CI 1.1-81.6, p = 0.04); more than one sex partner (AOR
2.5, 95% CI 1.1-6.1, p = 0.04); middle or high income
compared to low income subjects (AOR 2.2, 95% CI
1.4-3.3, p=0.001); subjects from nuclear family (AOR
1.7, 95% CI 1.1-2.6, p = 0.02); subjects with low level of
education (AOR 3.7, 95% CI 1.3-10.7, p = 0.02) and sub-
jects having regular earning through a regular job (AOR
3.4, 95% CI 1.3-8.8, p = 0.01) [see table 2]. Though
HSV-2 seroprevalence was higher amongst alcoholics
(12.1%) compared to non-alcoholics (7.7%), it was not
significant in multivariate analysis.
Table 1 State wise socio-demographic variables of the study subjects, Northeast India (n = 1640)
Variables (total) Manipur
n (%)
Assam
n (%)
Meghalaya
n (%)
Arunachal Pradesh
n (%)
Mizoram
n (%)
Subjects recruited (1640) 402 300 400 307 231
Age groups
18 to 21 yrs (355) 75(18.7) 77(25.7) 145(36.2) 30(9.8) 28(12.1)
22 to 25 yrs (592) 125(31.1) 137(45.6) 113(28.3) 140(45.6) 77(33.3)
26 to 29 yrs (385) 103(25.6) 63(21.0) 77(19.2) 85(27.7) 57(24.7)
> 29 yrs (308) 99(24.6) 23(7.7) 65(16.3) 52(16.9) 69(29.9)
Religion
Hindu (844) 346(86.1) 271(90.3) 93(23.2) 125(40.7) 9(3.9)
Christian (611) – 1(0.3) 280(70.0) 108(35.2) 222(96.1)
Muslim (106) 56(13.9) 26(8.7) 7(1.8) 17(5.5) –
Others (79) – 2(0.7) 20(5.0) 57(18.6) –
Occupation
House wife (1310) 341(84.8) 293(97.7) 328(82.0) 168(54.7) 180(77.9)
Regular employee (110) 7(1.7) 1(0.3) 17(4.2) 79(25.7) 6(2.6)
Unskilled worker (75) 39(9.7) 6(2.0) 50(12.5) 37(12.1) 43(18.6)
Business (45) 15(3.7) – 5(1.3) 23(7.5) 2(0.9)
Education
Primary & less (1063) 252(62.7) 231(77.0) 278(69.5) 166(54.1) 136(58.9)
Secondary (462) 105(26.1) 66(22.0) 101(25.2) 98(31.9) 92(39.8)
Graduate & above (115) 45(11.2) 3(1.0) 21(5.3) 43(14.0) 3(1.3)
Type of family
Nuclear (950) 232(57.7) 144(48.0) 238(59.5) 211(68.7) 125(54.1)
Joint (616) 169(42.0) 147(49.0) 156(39.0) 42(13.7) 102(44.2)
Single (74) 1(0.3) 9(3.0) 6(1.5) 54(17.6) 4(1.7)
Income group
Low (1177) 247(61.4) 262(87.3) 324(81.0) 160(52.1) 184(79.6)
Middle & high (463) 155(38.6) 38(12.67) 76(19.0) 147(47.88) 47(20.35)
Migrant labor (192) 14(3.5%) 14(4.7%) 78(19.5) 61(19.9%) 25(10.8%)
Duration of Pregnancy
1-12 weeks (28) – 9(3.0) 19(4.8) ––
13-28 weeks (513) 100(24.9) 205(68.3) 131(32.7) 39(12.7) 38(16.5)
29-42 weeks (1099) 302(75.1) 86(28.7) 250(62.5) 268(87.3) 193(83.5)
Commercial sex worker (8) 2(0.5%) –– 5(1.6%) 1(0.4%)
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seropositives were excess vaginal discharge in last one
year (53.5%, 76/142) and pelvic pain (26.1%, 37/142).
HSV-2 seroprevalence was highest, 36.8% (7/19; 95% CI
15.2-58.5) among subjects with genital ulcers. The
association of clinical signs & symptoms with HSV-2
seroprevalence is presented in Table 3. Significantly
higher HSV-2 seroprevalence was observed among
the subjects with genital ulcer (AOR 4.1, 95% CI 1.4-
12.2, p = 0.01), history of pelvic pain (AOR 2.2, 95%
Table 2 Risk factors associated with HSV-2 seroprevalence among pregnant women in Northeast India (n = 1640)
Characteristics (n) HSV-2 Sero
Prevalence
n (%)
Univariate analysis Multivariate analysis
OR 95%
C.I.
p value AOR 95%
C.I.
p value
Age groups
18 to 21 yrs (355) 23 (6.5) Ref –– Ref ––
22 to 25 yrs (592) 62 (10.5) 1.69 1.03-2.78 0.04 1.90 1.09-3.31 0.02
26 to 29 yrs (385) 28 (7.3) 1.13 0.64-2.01 0.67 1.52 0.81-2.87 0.19
> 29 yrs (308) 29 (9.4) 1.50 0.85-2.65 0.16 2.29 1.19-4.39 0.01
States
Manipur (402) 11 (2.7) Ref –– Ref ––
Assam (300) 12 (4.0) 1.48 0.64-3.40 0.36 2.30 0.96-5.48 0.06
Meghalaya (400) 42 (10.5) 4.17 2.11-8.22 < 0.001 5.13 2.52-10.43 < 0.001
Mizoram (231) 31 (13.4) 5.51 2.71-11.2 < 0.001 4.51 2.15-9.49 < 0.001
Arunachal Pradesh (307) 46 (15.0) 6.27 3.19-12.3 < 0.001 11.49 5.18-25.48 < 0.001
Occupation
Unskilled worker (75) 12 (6.9) Ref –– Ref ––
House wife (1310) 105 (8.0) 1.18 0.64-2.20 0.59 1.55 0.80-3.00 0.20
Business (45) 6 (13.3) 2.09 0.74-5.92 0.17 2.28 0.72-7.20 0.16
Regular employee (110) 19 (17.3) 2.84 1.32-6.11 0.008 3.45 1.35-8.81 0.01
Education
Graduate & above (115) 6 (5.2) Ref –– Ref ––
Secondary (462) 42 (9.1) 1.82 0.75-4.38 0.18 2.57 0.92-7.19 0.07
Primary & less (1063) 94 (8.8) 1.76 0.75-4.12 0.19 3.73 1.29-10.75 0.02
Type of family
Joint (616) 35 (5.7) Ref –– Ref ––
Nuclear (990) 99 (10.4) 1.93 1.30-2.88 0.001 1.66 1.08-2.57 0.02
Single (74) 8 (10.8) 2.01 0.90-4.52 0.090 1.72 0.64-4.64 0.28
Income group
Low (1177) 85 (7.2) Ref –– Ref ––
Middle (463) 57 (12.3) 1.80 1.27-2.57 0.001 2.15 1.39-3.31 0.001
Coitarchal age
> 30 yrs (29) 1 (3.4) Ref –– Ref ––
18 to 30 yrs (1335) 91 (6.8) 2.05 0.28-15.2 0.48 2.36 0.29-19.40 0.43
< 18 yrs (218) 48 (22.0) 7.91 1.05-59.6 0.045 9.59 1.13-81.65 0.04
No response (58) 2 (3.4) 1.00 0.09-11.5 1.00 0.60 0.05-7.83 0.70
Alcohol use
Never user (1267) 97 (7.7) Ref –– Ref ––
Regular & occasional users (373) 45 (12.1) 1.66 1.14-2.41 0.008 1.18 0.74-1.86 0.49
Sex partner
Single (1601) 134 (8.4) Ref –– Ref ––
More than 1 (39) 8 (20.5) 2.83 1.27-6.27 0.01 2.50 1.02-6.13 0.045
Condom use
Regular & occasional users (341) 18 (5.3) Ref –– Ref ––
Never user (1299) 124 (9.5) 1.9 1.14-3.15 0.01 4.73 2.51-8.91 < 0.001
AOR: Adjusted Odds Ratio; 95% CI: 95% confidence interval; Coitarchal age: age at first intercourse
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1.4-3.4, p = 0.001).
Discussion
The conceptual importance of this study was largely
based on the increasing evidence that HSV-2 infection
has a synergistic activity on acquiring HIV infection and
this has been well documented [6-14,16,17]. Since there
were virtually no data on the prevalence of HSV-2 in the
community of Northeastern states of India, there was a
need to know the prevalence of this infection to plan an
intervention strategy especially in the high HIV prevalent
states of Northeast India. This sero-epidemiological
study was based on detection of HSV-2 IgG antibodies
against type specific glycoprotein G2. The HerpeSelect
HSV-2 IgG ELISA test (Focus Diagnostics), in an evalua-
tion study demonstrated a sensitivity of 96% in a group
of pregnant women and 95% in a STD population of men
and women. The specificity of Focus HSV-2 ELISA was
also high in these groups i.e. 97% in pregnant women
and 96% in the STD population [24]. The relative specifi-
city of the assay as compared to Western Blot assay
(Gold standard) in a low prevalent population was shown
to be 98.7% and relative sensitivity 100% as per instruc-
tion manual of the kit. Though, the kit used in our study
has a very high sensitivity and specificity, the false posi-
tivity of HSV-2 in low prevalence area cannot be ruled
out. We also acknowledge the limitations of statistical
test used in this cross-sectional study which may be
prone to residual confounding effect in comparison to
case control studies.
Our study detected a significant geographical variation
of HSV-2 seroprevalence which has also been observed
in an earlier study [22]. Community based studies con-
ducted elsewhere in India also reported wide variations
in seroprevalence [3,25]. One study from Chennai based
o ns t u d yo fa r o u n d3 0c o m m u n i t i e s ,r e p o r t e daw i d e
variation in prevalence of HSV-2 from 4.1 to 49.1% with
a mean prevalence of 15.3% [3]. Studies conducted
among the high risk groups showed highest seropreva-
lence (40% to 70%) [12,26-28]. In our study, we expected
highest HSV-2 prevalence in the state of Manipur, which
has the highest HIV prevalence in India and expected
lowest in the state of Arunachal Pradesh which has the
lowest HIV prevalence in the country [21]. But to the
contrary, we detected the lowest HSV-2 seroprevalence
in the state of Manipur (2.7%) and highest in the state of
Arunachal Pradesh (15%). This may be the result of the
widespread public awareness in the state of Manipur in
last two decades on practice of safe sex to fight HIV epi-
demic in that state, whereas such public awareness drive
is virtually absent in the state of Arunachal Pradesh.
In comparison to other National and international stu-
dies, our finding of 8.7% HSV-2 seroprevalence was rela-
tively low. A community based study in New Delhi
reported 8.6% seroprevalence among females, which is
similar to our findings [25]. Higher seroprevalence were
reported from Chennai (15.3%) in South India [3], central
India (12.4%) [29] and Gujarat (23.3%) in Western India
among women attending gynaecology OPD [30]. Sero-
prevalence of 7.5% among pregnant women from Jammu
& Kashmir, North India [31], and 7.0% among females
from Andhra Pradesh, South India was reported in a
community based study [32]. The National Health and
Nutrition Examination Survey (NHANES) surveillance
data from USA found HSV-2 seroprevalence of 20.9% in
US females aged ‘14 to 49 years’, with an overall seropre-
valence of 16.2% [33]. The HSV-2 seroprevalence among
15 to 49 years females in South Asian region was
reported to be 33.2%, whereas it was 19.4% globally [4].
In comparison to low income group, we observed sig-
nificantly higher HSV-2 seroprevalence among middle
or high income group. Studies in India and abroad also
observed association of socio-economic status (SES)
Table 3 Association of clinical sign & symptoms with HSV-2 seroprevalence among pregnant women of Northeast
India (n = 1640)
Clinical sign
&
symptoms
Response/findings (n) HSV-2 Sero prevalence
n (%)
Univariate analysis Multivariate analysis
OR 95% CI P
value
AOR 95% CI P
value
Cervicitis No (1447) 107 (7.4) Ref –– Ref ––
Yes (193) 35 (18.1) 2.80 1.8-4.2 < 0.001 2.14 1.36-3.38 0.001
Genital ulcer No (1621) 135 (8.3) Ref –– Ref ––
Yes (19) 07 (36.8) 6.42 2.5-16.6 < 0.001 4.11 1.38-12.21 0.011
Pelvic pain No (1423) 105 (7.4) Ref –– Ref ––
Yes (217) 37 (17.1) 2.58 1.72-3.87 < 0.001 2.20 1.40-3.45 0.001
Excess vaginal discharge No (1003)
Yes (637)
66 (6.6)
76 (11.9)
Ref
1.92
–
1.36-2.72
–
< 0.001
Ref
1.46
–
1.00-2.15
–
0.053
AOR: Adjusted Odds Ratio; 95% CI: 95% confidence interval
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Page 6 of 9with HSV-2 seroprevalence [3,25,34]. This has been
observed from both the previously mentioned study
from New Delhi [25], and Chennai [3]. In the study
from New Delhi, HSV-2 seroprevalence was found to be
more common in the urban middle class community
with higher average monthly income (12.6%) as com-
pared to urban slum with lower average monthly
income (3.1%) [25]. While, the study from Chennai
reported an independent association of community-level
factors like SES with HSV-2 sero-prevalence [3]. In
another study from Australia, found that HSV-2 sero-
prevalence was significantly lower in areas of low SES
than in high SES areas among both men and women for
all ages [34]. However, some other studies have reported
significant association between HSV-2 seropositivity and
lower income [35]. Though this paradox would be hard
to explain, it may be related to difference in risk beha-
vior among the different income groups. It was seen in
our study that majority of Muslim subjects (84.9%, 90/
106) were from low income group. It was also observed
that Muslim subjects had the lowest HSV-2 seropreva-
lence (3.8%) compared to Hindu (5.8%) and Christians
(12.6%), which may explain this finding in our study.
It is generally being observed that HSV-2 seropreva-
lence increases with increasing age [25,33,36,37]. In our
s t u d yw ea l s oo b s e r v e da ni n c r e a s ei np r e v a l e n c ew i t h
age (6.5% to 9.4%) but with a peak in prevalence (10.5%)
in the 22-25 years age group. This may reflect a rela-
tively recent introduction of HSV-2 in the community
which may have resulted in higher prevalence among
sexually active younger subjects rather than the older
subjects which didn’th a dt h ee x p o s u r et ot h ev i r u s
when they were sexually active in the past.
The risk factors for HSV-2 are well known and
include polygamous relationships/multiple sex partners’,
unsafe sex, increasing numbers of lifetime partners and
association with other STIs or GUD etc [7,16,35,38].
The strongest predictor for infection is a person’sn u m -
ber of lifetime sex partners [36]. In our study, it was
also observed that subjects with multiple sex partners
had significantly higher HSV-2 seroprevalence compared
to single sex partner. Moreover, it was seen that higher
coitarchal age was associated with a lower chance of
HSV-2 infection. The association of coitarchal age less
than 18 years or early age of first sex with seropreva-
lence was also observed in other studies [39,40]. In this
study, higher seroprevalence was found among Chris-
tians versus Muslims. This difference in prevalence with
religion (3.8% in Muslim compared to 12.6% among
Christians), may be due to practice of male circumcision
at infancy or early childhood by the spouses of the preg-
nant women among Muslims. Male circumcision lowers
the prevalence of HSV-2 or HPV has been reported in
some studies [41]. Subjects from nuclear family, middle
income group, low level of education, having regular
source of income, had a higher risk of HSV-2 infections.
Modifiable risk factors included, low coitarchal age,
never or low condom usage, and multiple sex partners,
which can be incorporated in awareness programs to
lower the transmission of HSV-2 in the community.
Our study found a significantly higher HSV-2 seropo-
sitive amongst subjects with sign and symptoms of gen-
ito-pelvic infections such as genital ulcer, pelvic pain
and cervicitis. In our study it was found that HSV-2 pre-
valence was higher among subjects with excessive vagi-
nal discharge but was not significant statistically. The
subjects with history of genital ulcers had the highest
HSV-2 seroprevalence among the study variables. Also,
it is known that majority of HSV2 seropositive people
shed virus whether or not they are aware of recurrent
genital lesions. Genital tract inflammation is evident in
“asymptomatic shedders” [42]. Studies conducted in
Surat and Delhi also observed higher HSV-2 seropreva-
lence in subjects with vaginal discharge and lower
abdominal or low backache [30,43].
In Northeast India, the impact of HSV-2 infection in
driving the HIV-1 epidemics is still not clear. Although
HSV-2 vaccines are still in clinical trials, acyclovir when
given continuously or episodically can reduce recurrence
of ulcers in individuals with HSV-2 infection. Though
clinical trials in Africa on use of acyclovir did not
reduce the risk of linked transmission of HIV-1 to cou-
ples, however it showed a reduction of plasma HIV-1
RNA level as well as 73% reduction in occurrence of
genital ulcers due to HSV-2 [44]. Multiple studies have
shown that a persistent increase of 0.5 log10 copy per
millilitre in the plasma HIV-1 level is associated with a
clinically shortened time for progression to AIDS [6].
The demonstration that dailya n t i - H S V - 2t h e r a p yc a n
reduce the viral load by this amount is thus of direct
importance for treatment. The study by Nagot et al.
underlines the findings of a 1989 study showing that
zidovudine plus acyclovir (ACV) was associated with
prolonged survival, as compared with zidovudine alone
[6]. The data from another controlled trial with HSV-2
suppressive therapy with acyclovir showed no evidence
of decreasing the incidence of HIV in Tanzania [45].
This landmark study fails to demonstrate the role of
acyclovir in decreasing the transmission of HIV among
HSV-2 seropositives. This is in contrary to the fact that
acyclovir is activated into a human herpes virus (HHV)
DNA polymerase inhibitor exclusively by HHV kinases.
It suppresses HIV-1 in HHV coinfected human tissues
but not in HHV free tissue or cell cultures [46]. Acyclo-
vir treatment in patients coinfected with HSV/HIV has
been observed to alter the disease course and decrease
HIV viral load which attributed to indirect effects of
HSV suppression on HIV replication [47]. Also, if we
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Page 7 of 9accept the fact that HSV-2 increases the risk of HIV
acquisition by 2-3 folds, than suppression of HSV-2 by
ACV which results in decrease genial ulceration and
inflammation would be expected to influence HIV
acquisition. Use of antivirals for suppression of HSV-2
for lowering the risk of HIV transmission cannot be
overlooked until more light is shed on this topic. Thera-
peutic options that provide a complete eradication of
HSV-2 including suppression of genital inflammation
may be more relevant for decreasing HIV transmission
in high HSV-2 prevalent regions.
Conclusions
The findings of this study which is first of its kind in
North-east India, has provided a baseline data on HSV-2
seroprevalence and risk factors for future in-depth stu-
dies. The data provides a useful epidemiologic signal for
a possible impending spike in HIV incidence among the
young age group (22-25 years) as is indicated by a higher
HSV-2 prevalence in this age group. Targeted public
health awareness campaigns directed at high risk groups
having multiple sexual partners, condom non-users, early
coitarchal age, Christian community etc. are needed to
be advocated for initiating successful intervention strate-
gies to control HSV-2 and indirectly limiting HIV epi-
demic in Northeast India.
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